Andelyn Biosciences Capacity Update October 2024: Cell & Gene Therapy

This webinar presents our DOE-based strategy to develop a scalable suspension platform for AAV vector production and purification in gene therapy. To tackle the complex challenges in AAV manufacturing, we combine reductionist and holistic approaches for end-to-end platform optimization. Progress is assessed by benchmarks of consistency in productivity and quality at each development stage.

A key outcome of our optimization studies is demonstrated consistency in productivity, purification, and quality across multiple scales. The result is a modular, adaptable platform with customizable options tailored to specific AAV transgenes, serotypes, and various cell lines.